Affiliation:
1. UNC Eshelman School of Pharmacy, UNC Lineberger Comprehensive Cancer Center, Caroline Institute of Nanomedicine University of North Carolina Chapel Hill NC USA
2. Office of Clinical Pharmacology, Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring MD USA
3. St. Jude Children's Research Hospital Memphis TN USA
Abstract
AbstractAn objective of the Precision Medicine Initiative, launched in 2015 by the US Food and Drug Administration and National Institutes of Health, is to optimize and individualize dosing of drugs, especially anticancer agents, with high pharmacokinetic and pharmacodynamic variability. The American Society of Clinical Oncology recently reported that 40% of obese patients receive insufficient chemotherapy doses and exposures, which may lead to reduced efficacy, and recommended pharmacokinetic studies to guide appropriate dosing in these patients. These issues will only increase in importance as the incidence of obesity in the population increases. This publication reviews the effects of obesity on (1) tumor biology, development of cancer, and antitumor response; (2) pharmacokinetics and pharmacodynamics of small‐molecule anticancer drugs; and (3) pharmacokinetics and pharmacodynamics of complex anticancer drugs, such as carrier‐mediated agents and biologics. These topics are not only important from a scientific research perspective but also from a drug development and regulator perspective. Thus, it is important to evaluate the effects of obesity on the pharmacokinetics and pharmacodynamics of anticancer agents in all categories of body habitus and especially in patients who are obese and morbidly obese. As the effects of obesity on the pharmacokinetics and pharmacodynamics of anticancer agents may be highly variable across drug types, the optimal dosing metric and algorithm for difference classes of drugs may be widely different. Thus, studies are needed to evaluate current and novel metrics and methods for measuring body habitus as related to optimizing the dose and reducing pharmacokinetic and pharmacodynamic variability of anticancer agents in patients who are obese and morbidly obese.
Subject
Pharmacology (medical),Pharmacology
Reference147 articles.
1. Obesity: global epidemiology and pathogenesis;Blüher M;Nat Rev Endocrinol,2019
2. Prevalence of obesity and severe obesity among adults: United States, 2017–2018;Hales CM;NCHS Data Brief,2020
3. Mechanisms, pathophysiology, and management of obesity;Heymsfield SB;N Engl J Med,2017
4. Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association;Bays HE;J Clin Lipidol,2013
5. Quantifying the sex‐race/ethnicity‐specific burden of obesity on incident diabetes mellitus in the United States, 2001 to 2016:MESA and NHANES;Cameron NA;J Am Heart Assoc,2021